Clinical Trial News and Research

RSS

BIDMC physician-scientist receives Young Investigator Award to research on prostate cancer

Akash Patnaik, MD, PhD, a physician-scientist in the Hematology/Oncology Divison at Beth Israel Deaconess Medical Center and Instructor of Medicine at Harvard Medical School has received a Young Investigator Award from The Prostate Cancer Foundation. The three-year $225,000 award, one of 21 made to young scientists from across the U.S. and Canada, is designed to encourage the most innovative minds in cancer research to focus their careers on prostate cancer.

1 Jul 2010

Biospherics acquires worldwide patent rights to Dtagatose from UKRF

Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome, and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its wholly-owned subsidiary, Biospherics Incorporated, has signed a license agreement with the University of Kentucky Research Foundation (UKRF).

1 Jul 2010

XOMA reaches enrollment goal of 325 patients for Phase 2b clinical trial of XOMA 052

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that it has reached the enrollment goal of 325 patients for its Phase 2b dose-ranging clinical trial of XOMA 052, and that it expects patient enrollment to close in July 2010, with top-line results available in the first quarter of 2011. XOMA 052 is a therapeutic antibody candidate that inhibits the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta) which drives the inflammatory cause of Type 2 diabetes.

1 Jul 2010

Gen-Probe's APTIMA Trichomonas assay receives European CE mark

Gen-Probe Incorporated announced today that it has received a European CE mark for its APTIMA® assay for Trichomonas vaginalis, a common parasitic sexually transmitted disease.

1 Jul 2010

Eisai reports preliminary results from Dacogen for Injection Phase III study in AML

Eisai Inc. announced today preliminary results from a randomized Phase III clinical trial of Dacogen® (decitabine) for Injection versus either a low-dose chemotherapy agent or supportive care in elderly patients with acute myeloid leukemia (AML), a life-threatening cancer of the blood that generally occurs in older adults.

1 Jul 2010

Threshold Pharmaceuticals initiates Phase 2 clinical trial of TH-302 in patients with first line pancreatic cancer

Threshold Pharmaceuticals, Inc. today announced that it has initiated a multi-center, randomized, controlled, crossover Phase 2 clinical trial of TH-302 in combination with gemcitabine in patients with first line pancreatic cancer. TH-302 is a proprietary tumor selective Hypoxia-Activated Prodrug that specifically targets tumor hypoxia.

1 Jul 2010

Neuralstem announces completion of $10 million registered direct offering

Neuralstem, Inc. (NYSE Amex: CUR) announced that it has completed its previously announced registered direct offering of $10 million of units to institutional investors. The units were priced at $2.80 and consisted of: (i) one share of common stock, and (ii) 3/4 common stock purchase warrant. The warrants have an exercise price of $3.25 and a term of three years. Net proceeds from this offering, after deducting placement agent fees and other offering expenses, total approximately $9.2 million. All of the securities were offered pursuant to an effective shelf registration statement.

1 Jul 2010

USPTO issues Notice of Allowance for patent application related to Neogenix Oncology's 16C3 antibody

Neogenix Oncology announced today that the U.S. Patent and Trade Mark Office has issued a Notice of Allowance for a patent application related to its 16C3 antibody. Discovered and developed by Neogenix Oncology, this antibody appears to have anti-tumor activity for both pancreatic and colorectal tumors, and may have both therapeutic and diagnostic utility. The antibody may have activity in other tumors as well, which the company will explore at such time as it prepares a pre-IND package for FDA review and designs a clinical trial for the 16C3 antibody.

1 Jul 2010

SuperGen encouraged by Eisai's intent to file Dacogen sNDA for new indication

SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced that Eisai Inc. today released information regarding a randomized Phase III clinical trial of Dacogen® (decitabine) for Injection in elderly patients with acute myeloid leukemia (AML). The comparator in this trial was low-dose cytarabine, a chemotherapy agent, or supportive care.

30 Jun 2010

Calistoga Pharmaceuticals closes $40 million Series C financing

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced it has closed a $40 million Series C financing. The financing was led by Quogue Capital, LLC along with existing investors Alta Partners, Amgen Ventures, Frazier Healthcare and Three Arch Partners and new investor Latterell Venture Partners.

30 Jun 2010

BioSante reports positive results from Phase II study of Pill-Plus "triple hormone" oral contraceptive

BioSante Pharmaceuticals, Inc. announced today positive results in a Phase II study of the Pill-Plus "triple hormone" oral contraceptive (OC). Results showed an increase in the frequency of sexual activity (p< 0.05) and reduced frequency of rejection of initiation of sexual activity by partner (p< 0.05).

30 Jun 2010

Raptor partners with Uni Pharma to commercialize Convivia in Taiwan

Raptor Pharmaceutical Corp., announced that it has entered into an exclusive agreement with Uni Pharma Co., Ltd. to commercialize Convivia™, Raptor's proprietary oral formulation of 4-methylpyrazole, in Taiwan.

30 Jun 2010

Vitrified eggs as likely to produce on-going pregnancy as fresh eggs

Embryos derived from oocytes (eggs) cryopreserved by the vitrification method are just as likely to produce an on-going pregnancy as those involving fresh oocytes, the 26th annual meeting of the European Society of Human Reproduction and Embryology heard today. Dr. Ana Cobo, Cryobiology Unit director at Institut Universitari - IVI Valencia, Valencia, Spain, told delegates that the results of her team's research would make egg donation both easier and safer in the future.

30 Jun 2010

NORD urges FDA to reduce regulatory uncertainty in developing medicines for rare disorders

Noting that only about 200 of the nearly 7,000 diseases classified as rare currently have treatments, the National Organization for Rare Disorders (NORD) today called for a Food and Drug Administration (FDA) statement of policy on regulation of therapies for rare disorders.

30 Jun 2010

Asbestos induces cell necrosis, promotes tumor growth

More than 20 million people in the U.S., and many more worldwide, who have been exposed to asbestos are at risk of developing mesothelioma, a malignant cancer of the membranes that cover the lungs and abdomen that is resistant to current therapies.

30 Jun 2010

Preliminary findings show RA drug reduces brain damage in stroke patients

A drug used to treat rheumatoid arthritis also reduces the damage a stroke inflicts on the brain according to lab research and preliminary findings from a clinical trial of stroke patients. The results open the door for a larger clinical study to refine the drug anakinra's use as an effective therapy for victims of stroke.

From The University of Manchester 30 Jun 2010

Sangart completes enrollment for MP4OX Phase IIa study in severely injured trauma patients

Sangart, Inc., today announced that enrollment was completed in a Phase IIa clinical study of MP4OX (oxygenated pegylated hemoglobin) in severely injured trauma patients with hemorrhagic shock causing lactic acidosis. Complete study results are expected, after follow up of outcomes in these patients, in the second half of 2010.

30 Jun 2010

FDA grants IND regulatory clearance for Phase I/II clinical trial of AAT in type 1 diabetics

The U.S. Food & Drug Administration (FDA) has granted Investigational New Drug (IND) regulatory clearance to initiate a Phase I/II clinical trial evaluating Alpha-1 Antitrypsin (AAT) in type 1 diabetics, based on research by Dr. Eli Lewis of Israel's Ben-Gurion University of the Negev.

30 Jun 2010

Study indicates two treatment strategies can reduce progression of diabetic retinopathy

In high-risk adults with type 2 diabetes, researchers have found that two therapies may slow the progression of diabetic retinopathy, an eye disease that is the leading cause of vision loss in working-age Americans.

30 Jun 2010

Cardio3 BioSciences reports positive data from C-Cure stem cell therapy clinical trial for heart failure

Cardio3 BioSciences, a leading Belgian biotechnology company specialising in regenerative therapies for the treatment of cardiovascular diseases, today announces positive safety data and preliminary efficacy results from its clinical trial of C-Cure(R), a breakthrough stem cell therapy for heart failure.

30 Jun 2010

Clinical Trial News and Research

BIDMC physician-scientist receives Young Investigator Award to research on prostate cancer

Biospherics acquires worldwide patent rights to Dtagatose from UKRF

XOMA reaches enrollment goal of 325 patients for Phase 2b clinical trial of XOMA 052

Gen-Probe's APTIMA Trichomonas assay receives European CE mark

Eisai reports preliminary results from Dacogen for Injection Phase III study in AML

Threshold Pharmaceuticals initiates Phase 2 clinical trial of TH-302 in patients with first line pancreatic cancer

Neuralstem announces completion of $10 million registered direct offering

USPTO issues Notice of Allowance for patent application related to Neogenix Oncology's 16C3 antibody

SuperGen encouraged by Eisai's intent to file Dacogen sNDA for new indication

Calistoga Pharmaceuticals closes $40 million Series C financing

BioSante reports positive results from Phase II study of Pill-Plus "triple hormone" oral contraceptive

Raptor partners with Uni Pharma to commercialize Convivia in Taiwan

Vitrified eggs as likely to produce on-going pregnancy as fresh eggs

NORD urges FDA to reduce regulatory uncertainty in developing medicines for rare disorders

Asbestos induces cell necrosis, promotes tumor growth

Preliminary findings show RA drug reduces brain damage in stroke patients

Sangart completes enrollment for MP4OX Phase IIa study in severely injured trauma patients

FDA grants IND regulatory clearance for Phase I/II clinical trial of AAT in type 1 diabetics

Study indicates two treatment strategies can reduce progression of diabetic retinopathy

Cardio3 BioSciences reports positive data from C-Cure stem cell therapy clinical trial for heart failure

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News